Compare iShares MSCI Hong Kong ETF (EWH) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Hong Kong ETF vs Gilead Sciences, Inc. — how do they compare? iShares MSCI Hong Kong ETF trades at $22.04, while Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B). The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares MSCI Hong Kong ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares MSCI Hong Kong ETF nearer its low. Which is the better fit depends on your goals.
| EWH | GILD | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $24.55 | $155.80 |
52-Week Low | $20.15 | $108.22 |
Market Cap | — | $163.51B |
Enterprise Value | — | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWH, the iShares MSCI Hong Kong ETF, trades at $22.04, up 1.71% with a bullish technical signal from moving averages. The ETF tracks Hong Kong equities, showing recent momentum in Chinese technology stocks as highlighted in recent market coverage. Key resistance and support cluster around $22, while RSI readings suggest potential overbought conditions. The fund declared a $0.35 dividend payable in June 2026.
Outlook remains tied to Hong Kong market performance and Chinese economic factors. Positive catalysts include technology sector rallies and Hong Kong's growing wealth hub status, but risks involve regulatory scrutiny on Chinese brokerages and IPO performance concerns. Investor sentiment is cautiously optimistic amid regional market volatility.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
